Skip to main content
main-content

The independent medical news service

26-05-2022 | Oncology | News | Article

Antibiotics tied to poor NSCLC, melanoma TKI outcomes

Antibiotic use is associated with poor survival outcomes in people receiving tyrosine kinase inhibitors for advanced non-small-cell lung cancer or melanoma, findings indicate.

27-04-2022 | Oncology | News | Article

Neurologic AE risk lower with ICIs vs chemotherapy

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

08-11-2021 | Oncology | News | Article

ICI monotherapy benefits cancer patients aged 80 and older

Age alone should not preclude the use of immune checkpoint inhibitors in people with cancer aged 80 years or more, say researchers who found promising efficacy and tolerability of single-agent therapy in this patient population.

26-10-2021 | Oncology | News | Article

ICIs linked to increased venous thromboembolism risk

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.

16-07-2021 | Oncology | News | Article

Ex vivo tumor platform gives window to PD-1 blockade response

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

15-04-2020 | Oncology | News | Article

Long noncoding RNA signatures may help predict immunotherapy response

Chinese researchers have used a combination of long noncoding RNA signatures and cytotoxic T-lymphocyte tumor infiltration to identify four distinct immune classes that may predict response to cancer immunotherapy.